Mode
Text Size
Log in / Sign up

taVNS with ropivacaine block reduces chronic postsurgical pain after off-pump CABG in elderly patients

taVNS with ropivacaine block reduces chronic postsurgical pain after off-pump CABG in elderly patien…
Photo by Pharmacy Images / Unsplash
Key Takeaway
Consider taVNS for reducing chronic pain after CABG in elderly patients, based on a single RCT with modest effect.

This randomized controlled trial enrolled 260 elderly patients (≥60 years) undergoing off-pump coronary artery bypass grafting (OPCABG). Participants received either transcutaneous auricular vagus nerve stimulation (taVNS) with a pectoral-intercostal fascial block (PIFB) using ropivacaine, or a sham taVNS with a placebo PIFB.

The primary outcome was the incidence of chronic postsurgical pain (CPSP) at 3 months postoperatively. The overall CPSP incidence was 34.6%. taVNS significantly reduced CPSP incidence compared to sham (28.6% vs 40.9%, p=0.036). PIFB did not significantly reduce overall CPSP incidence compared to placebo (30.2% vs 38.8%, p=0.143). taVNS also alleviated acute pain and improved recovery quality, though specific numbers were not reported. PIFB reduced moderate-to-severe CPSP, but absolute numbers were not reported.

A mediation analysis indicated that taVNS benefits were partially mediated by reducing acute pain (19.3%) and IL-6 levels (20.4%). Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the abstract.

Key limitations include that the follow-up duration was reported as 720.0 months, which is likely a data entry error, and other limitations were not reported in the abstract. The practice relevance notes that perioperative taVNS significantly reduced CPSP incidence and enhanced postoperative recovery in elderly OPCABG patients, while a single-shot PIFB showed limited preventive effect on overall CPSP.

Given this is a single RCT, certainty may be limited by sample size and follow-up duration. Results should not be overgeneralized to all surgical populations or assumed to have long-term effects beyond 3 months without further data.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up720.0 mo
PublishedJan 2026
View Original Abstract ↓
BACKGROUND: Chronic postsurgical pain (CPSP) is common after off-pump coronary artery bypass grafting (OPCABG) in elderly patients. This trial investigated the efficacy of perioperative transcutaneous auricular vagus nerve stimulation (taVNS) and pectoral-intercostal fascial block (PIFB) for CPSP prevention. METHODS: In this 2×2 factorial trial, 260 elderly patients (≥60 years) undergoing OPCABG were randomized to taVNS + ropivacaine PIFB, taVNS + placebo PIFB, sham taVNS + ropivacaine PIFB, or sham taVNS + placebo PIFB groups. The primary outcome was CPSP incidence at 3 months postoperatively. Several secondary outcomes were evaluated. Logistic regression was employed to analyze risk factors associated with CPSP. Lastly, mediation analyses were performed to explore the mediating factors between interventions and CPSP. RESULTS: The overall incidence of CPSP was 34.6%. No interaction was found between taVNS and PIFB. Compared with sham taVNS, taVNS significantly reduced CPSP incidence (28.6% vs 40.9%, = 0.036), alleviated acute pain and improved recovery quality. PIFB did not reduce overall CPSP incidence (30.2% vs 38.8%, = 0.143), though it alleviated acute pain on postoperative day 1 and reduced moderate-to-severe CPSP. Risk factors for CPSP included preoperative anxiety, pain catastrophizing, acute postoperative pain, and high IL-6 levels. Mediation analysis indicated taVNS's benefits were partially mediated by reducing acute pain (19.3%) and IL-6 (20.4%). CONCLUSION: Perioperative taVNS significantly reduced CPSP incidence and enhanced postoperative recovery in elderly OPCABG patients, partly mediated by alleviating acute pain and inflammation. Single-shot PIFB showed limited preventive effect on overall CPSP.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.